Jonathan Javitt, MD, MPH, Founder, Chairman, and Chief Scientist of NRx Pharmaceuticals, gives the keynote address “Ketamine for Suicidal Depression: The Benefits are Clear, But So are the Risks,” at the Sachs Neuroscience Innovation Forum in San Francisco, CA on January 7, 2024.
Broadcasts
The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H., Chairman and Chief Scientist, NRx Pharmaceuticals, discussing the anti-depressant effect of Ketamine.
The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing NRx-101 – the first investigational drug in FDA trials for suicidal bipolar depression.
Veteran broadcaster Jane King from the NASDAQ MarketSite in Times Square interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing NRx-101 – the first investigational drug in FDA trials for suicidal bipolar depression.
Cheddar News – Apr 15, 2021 12:02 am
Cheddar News – Apr 2, 2021 02:23 pm
Interview with Dr. Yo – Streamed live on Feb 11, 2021
Fox Business Apr. 07, 2021 – 5:06 – NeuroRX CEO Dr. Jonathan Javitt discusses the new COVID-19 drug for respiratory distress and vaccine boosters.
University of Miami Health System